vs
Eventbrite, Inc.（EB）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是Eventbrite, Inc.的1.9倍（$139.1M vs $73.5M），VERACYTE, INC.净利率更高（20.6% vs -11.1%，领先31.8%），VERACYTE, INC.同比增速更快（21.5% vs -3.9%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
EB vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.9倍
$73.5M
营收增速更快
VCYT
高出25.4%
-3.9%
净利率更高
VCYT
高出31.8%
-11.1%
两年增速更快
VCYT
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $139.1M |
| 净利润 | $-8.2M | $28.7M |
| 毛利率 | 68.1% | 72.7% |
| 营业利润率 | -12.4% | 16.3% |
| 净利率 | -11.1% | 20.6% |
| 营收同比 | -3.9% | 21.5% |
| 净利润同比 | 2.5% | — |
| 每股收益（稀释后） | $-0.08 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $73.5M | $140.6M | ||
| Q3 25 | $71.7M | $131.9M | ||
| Q2 25 | $72.8M | $130.2M | ||
| Q1 25 | $73.8M | $114.5M | ||
| Q4 24 | $76.5M | $118.6M | ||
| Q3 24 | $77.8M | $115.9M | ||
| Q2 24 | $84.6M | $114.4M |
净利润EBVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $-8.2M | $41.1M | ||
| Q3 25 | $6.4M | $19.1M | ||
| Q2 25 | $-2.1M | $-980.0K | ||
| Q1 25 | $-6.6M | $7.0M | ||
| Q4 24 | $-8.4M | $5.1M | ||
| Q3 24 | $-3.8M | $15.2M | ||
| Q2 24 | $1.1M | $5.7M |
毛利率EBVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 68.1% | 72.5% | ||
| Q3 25 | 67.9% | 69.2% | ||
| Q2 25 | 67.5% | 69.0% | ||
| Q1 25 | 66.9% | 69.5% | ||
| Q4 24 | 68.2% | 66.4% | ||
| Q3 24 | 68.5% | 68.2% | ||
| Q2 24 | 70.9% | 68.1% |
营业利润率EBVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | -12.4% | 26.4% | ||
| Q3 25 | -1.3% | 17.4% | ||
| Q2 25 | -8.7% | -4.0% | ||
| Q1 25 | -13.2% | 2.5% | ||
| Q4 24 | -10.2% | 3.5% | ||
| Q3 24 | -11.5% | 10.4% | ||
| Q2 24 | -7.6% | 4.0% |
净利率EBVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | -11.1% | 29.3% | ||
| Q3 25 | 8.9% | 14.5% | ||
| Q2 25 | -2.9% | -0.8% | ||
| Q1 25 | -9.0% | 6.2% | ||
| Q4 24 | -11.0% | 4.3% | ||
| Q3 24 | -4.8% | 13.1% | ||
| Q2 24 | 1.3% | 5.0% |
每股收益（稀释后）EBVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $-0.08 | $0.50 | ||
| Q3 25 | $0.06 | $0.24 | ||
| Q2 25 | $-0.02 | $-0.01 | ||
| Q1 25 | $-0.07 | $0.09 | ||
| Q4 24 | $-0.09 | $0.07 | ||
| Q3 24 | $-0.04 | $0.19 | ||
| Q2 24 | $0.01 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $439.1M |
| 总债务越低越好 | $144.4M | — |
| 股东权益账面价值 | $179.1M | $1.3B |
| 总资产 | $647.2M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.81× | — |
8季度趋势，按日历期对齐
现金及短期投资EBVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $299.9M | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | $441.5M | $239.1M | ||
| Q3 24 | $24.7M | $274.1M | ||
| Q2 24 | $56.7M | $235.9M |
总债务EBVCYT
| Q1 26 | — | — | ||
| Q4 25 | $144.4M | — | ||
| Q3 25 | $174.9M | — | ||
| Q2 25 | $241.3M | — | ||
| Q1 25 | $241.0M | — | ||
| Q4 24 | $240.7M | — | ||
| Q3 24 | $240.4M | — | ||
| Q2 24 | $358.7M | — |
股东权益EBVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $179.1M | $1.3B | ||
| Q3 25 | $189.1M | $1.3B | ||
| Q2 25 | $177.2M | $1.2B | ||
| Q1 25 | $173.3M | $1.2B | ||
| Q4 24 | $170.2M | $1.2B | ||
| Q3 24 | $179.8M | $1.2B | ||
| Q2 24 | $176.2M | $1.1B |
总资产EBVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $647.2M | $1.4B | ||
| Q3 25 | $744.6M | $1.4B | ||
| Q2 25 | $784.1M | $1.3B | ||
| Q1 25 | $812.3M | $1.3B | ||
| Q4 24 | $752.3M | $1.3B | ||
| Q3 24 | $817.4M | $1.3B | ||
| Q2 24 | $894.5M | $1.2B |
负债/权益比EBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | — | ||
| Q3 25 | 0.92× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 2.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | — |
| 自由现金流率自由现金流/营收 | -82.8% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $17.6M | — |
8季度趋势，按日历期对齐
经营现金流EBVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $-60.8M | $52.6M | ||
| Q3 25 | $36.7M | $44.8M | ||
| Q2 25 | $-17.5M | $33.6M | ||
| Q1 25 | $59.4M | $5.4M | ||
| Q4 24 | $-45.3M | $24.5M | ||
| Q3 24 | $44.6M | $30.0M | ||
| Q2 24 | $-32.3M | $29.6M |
自由现金流EBVCYT
| Q1 26 | — | — | ||
| Q4 25 | $-60.9M | $48.8M | ||
| Q3 25 | $36.6M | $42.0M | ||
| Q2 25 | $-17.5M | $32.3M | ||
| Q1 25 | $59.4M | $3.5M | ||
| Q4 24 | $-45.3M | $20.4M | ||
| Q3 24 | $44.4M | $27.7M | ||
| Q2 24 | $-32.4M | $26.8M |
自由现金流率EBVCYT
| Q1 26 | — | — | ||
| Q4 25 | -82.8% | 34.7% | ||
| Q3 25 | 51.1% | 31.8% | ||
| Q2 25 | -24.1% | 24.8% | ||
| Q1 25 | 80.4% | 3.1% | ||
| Q4 24 | -59.2% | 17.2% | ||
| Q3 24 | 57.1% | 23.9% | ||
| Q2 24 | -38.3% | 23.4% |
资本支出强度EBVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 2.7% | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.1% | 1.6% | ||
| Q4 24 | 0.0% | 3.5% | ||
| Q3 24 | 0.2% | 1.9% | ||
| Q2 24 | 0.1% | 2.4% |
现金转化率EBVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 5.76× | 2.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | -30.37× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
